{"id":"human-papillomavirus-tumor-antigen-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine works by introducing HPV tumor antigens to the body, which triggers an immune response and helps to prevent HPV-related diseases.","oneSentence":"Stimulates an immune response against Human Papillomavirus (HPV) tumor antigens","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:00:43.812Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical, vulvar, vaginal, penile, and anal cancers caused by Human Papillomavirus"}]},"trialDetails":[{"nctId":"NCT05108870","phase":"PHASE1, PHASE2","title":"TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-07-17","conditions":"Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":98},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT06508138","phase":"PHASE1","title":"Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection","status":"ENROLLING_BY_INVITATION","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-18","conditions":"HPV 16 Infection, HPV-Related Carcinoma, Recurrence","enrollment":24},{"nctId":"NCT05232851","phase":"PHASE1, PHASE2","title":"A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-06-16","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma","enrollment":20},{"nctId":"NCT06319963","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Theravectys S.A.","startDate":"2024-08-08","conditions":"HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":72},{"nctId":"NCT05799144","phase":"PHASE2","title":"pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Michael K. Gibson","startDate":"2023-05-16","conditions":"Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma","enrollment":54},{"nctId":"NCT06315257","phase":"PHASE1","title":"A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-09-22","conditions":"Cervical Cancer","enrollment":32},{"nctId":"NCT04180215","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers","status":"COMPLETED","sponsor":"Hookipa Biotech GmbH","startDate":"2019-12-11","conditions":"HPV-Related Squamous Cell Carcinoma","enrollment":198},{"nctId":"NCT00092534","phase":"PHASE3","title":"Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06-14","conditions":"Cervical Cancer, Genital Warts","enrollment":12167},{"nctId":"NCT05357898","phase":"PHASE1, PHASE2","title":"Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"SQZ Biotechnologies","startDate":"2022-03-24","conditions":"Adult Solid Tumor","enrollment":20},{"nctId":"NCT00788164","phase":"PHASE1","title":"Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-11","conditions":"Cervical Cancer, Precancerous Condition, HPV Disease","enrollment":75},{"nctId":"NCT04084951","phase":"PHASE1","title":"Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"SQZ Biotechnologies","startDate":"2020-01-28","conditions":"Adult Solid Tumor","enrollment":30},{"nctId":"NCT05694728","phase":"PHASE2","title":"A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine","status":"COMPLETED","sponsor":"Beijing Health Guard Biotechnology, Inc","startDate":"2020-05-23","conditions":"Human Papilloma Virus Infection","enrollment":780},{"nctId":"NCT05680454","phase":"PHASE1","title":"A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine","status":"COMPLETED","sponsor":"Beijing Health Guard Biotechnology, Inc","startDate":"2019-09-01","conditions":"Human Papillomavirus Infection","enrollment":160},{"nctId":"NCT02529930","phase":"PHASE1, PHASE2","title":"An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)","status":"COMPLETED","sponsor":"Nykode Therapeutics ASA","startDate":"2015-08","conditions":"High Grade Cervical Intraepithelial Neoplasia","enrollment":34},{"nctId":"NCT05149248","phase":"PHASE2, PHASE3","title":"Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2018-05-30","conditions":"Cancer of Cervix","enrollment":6000},{"nctId":"NCT01492582","phase":"PHASE2","title":"Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2012-07","conditions":"Cancer Survivor, Prevention of Human Papillomavirus Infection","enrollment":1499},{"nctId":"NCT01735006","phase":"PHASE3","title":"Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine","status":"COMPLETED","sponsor":"Xiamen University","startDate":"2012-11-22","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":7372},{"nctId":"NCT02947854","phase":"PHASE1","title":"Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant","status":"COMPLETED","sponsor":"PCI Biotech AS","startDate":"2016-09","conditions":"Healthy Volunteer","enrollment":96},{"nctId":"NCT01245764","phase":"PHASE3","title":"GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-21","conditions":"Papillomavirus Infections","enrollment":250},{"nctId":"NCT02576561","phase":"PHASE2","title":"Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL","status":"UNKNOWN","sponsor":"THEVAX Genetics Vaccine","startDate":"2015-11","conditions":"Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions","enrollment":10},{"nctId":"NCT00411749","phase":"PHASE2","title":"V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-11","conditions":"HPV Infections","enrollment":107},{"nctId":"NCT00524745","phase":"NA","title":"Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil","status":"COMPLETED","sponsor":"PATH","startDate":"2007-10","conditions":"Dose Schedule Study","enrollment":903},{"nctId":"NCT01598792","phase":"PHASE1","title":"Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer","status":"TERMINATED","sponsor":"University of Liverpool","startDate":"2012-02","conditions":"HPV-16 +ve Oropharyngeal Carcinoma","enrollment":2},{"nctId":"NCT01356823","phase":"PHASE2","title":"Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine","status":"COMPLETED","sponsor":"Xiamen University","startDate":"2011-03","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer","enrollment":1600},{"nctId":"NCT00002916","phase":"PHASE2","title":"Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1996-11","conditions":"Cervical Cancer","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Human Papillomavirus Tumor Antigen Vaccine","genericName":"Human Papillomavirus Tumor Antigen Vaccine","companyName":"Michael K. Gibson","companyId":"michael-k-gibson","modality":"Biologic","firstApprovalDate":"","aiSummary":"Stimulates an immune response against Human Papillomavirus (HPV) tumor antigens Used for Prevention of cervical, vulvar, vaginal, penile, and anal cancers caused by Human Papillomavirus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}